Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 9,555 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 2, 2024, Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., sold 9,555 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• The shares were sold at a weighted average price of $8.7378, with individual trades ranging from $8.47 to $9.07.
• Following the transaction, Burnett directly owns 259,745 shares of Arcutis Biotherapeutics common stock.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction for tax purposes and doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is often viewed positively as it demonstrates that the insider's trading activity is planned and not based on inside information.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations from vesting equity. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Sales to cover tax obligations are common among executives in publicly traded companies.
• The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, similar to practices at companies like Amgen or Regeneron.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the use of a 10b5-1 plan mitigates this concern.

Key Dates